TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Alumis Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Na
Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2.65 million shares. Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are serving as joint book-running managers.

Insights
ALMS   positive

The company successfully priced an upsized public offering at $17.00 per share, raising $300 million to fund its clinical-stage drug development pipeline. The upsizing of the offering and strong pricing indicate investor confidence in the company's therapeutic candidates, particularly its lead program envudeucitinib for immune-mediated diseases.